Launch week offerEnds in00h00m00s

Paul Hofman

Head of the Department

Centre Hospitalier Universitaire de Nice
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Professor Paul Hofman is a faculty member at Université Côte d’Azur, France. His research focuses on the molecular diagnostics of lung cancer, including genomic alterations and the implementation of biomarker testing. His recent publications emphasize topics such as mutation testing in non-small cell lung cancer and the cost-effectiveness of various diagnostic approaches. Professor Hofman aims to improve cancer care through innovative research in precision medicine and therapeutic strategies.

Articles (30)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Understanding the diversity in cancer research priorities and the correlations among different treatment modalities is essential to address the evolving landscape of oncology. This study, conducted in collaboration with the European Cancer Patient Coalition (ECPC) and Childhood Cancer International-Europe (CCI-E) as part of the “UNCAN.eu” initiative, analyzed data from a comprehensive survey to explore the complex interplay of demographics, time since cancer diagnosis, and types of treatments received. Demographic analysis revealed intriguing trends, highlighting the importance of tailoring cancer research efforts to specific age groups and genders. Individuals aged 45–69 exhibited highly aligned research priorities, emphasizing the need to address the unique concerns of middle-aged and older populations. In contrast, patients over 70 years demonstrated a divergence in research priorities, underscoring the importance of recognising the distinct needs of older individuals in cancer research. The analysis of correlations among different types of cancer treatments underscored the multidisciplinary approach to cancer care, with surgery, radiotherapy, chemotherapy, precision therapy, and biological therapies playing integral roles. These findings support the need for personalized and combined treatment strategies to achieve optimal outcomes. In conclusion, this study provides valuable insights into the complexity of cancer research priorities and treatment correlations in a European context. It emphasizes the importance of a multifaceted, patient-centred approach to cancer research and treatment, highlighting the need for ongoing support, adaptation, and collaboration to address the ever-changing landscape of oncology.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (35)

Ming Sound Tsao

Director (Princess Margaret Cancer Centre Living Biobank Core Facility)

University Health Network

CANADA
View details

Baharia Mograbi

-

FRANCE
View details

Caterina De Luca

University of Naples Federico II

ITALY
View details

Enrique de Alava

Professor

Universidad de Sevilla

SPAIN
View details

Umberto Malapelle

-

ITALY
View details

Catherine Alix-Panabières

Director/Professor

University Hospital of Montpellier

FRANCE
View details

Philippe Bahadoran

-

FRANCE
View details

Martin von Bergen

Head of Department

Helmholtz Centre for Environmental Research

GERMANY
View details

Petros Christopoulos

-

GERMANY
View details

Fernando Schmitt

Professor

Universidade do Porto Faculdade de Medicina

PORTUGAL
View details

Yongsoo Kim

Assistant professor

Amsterdam University Medical Centers

NETHERLANDS
View details

Edwin Roger Parra

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marius Ilié

Professor, PU-PH

Centre Hospitalier Universitaire de Nice

FRANCE
View details

Charles Hugo Marquette

Full time professor

Université Côte d'Azur

FRANCE
View details

Eric Solary

Full-Professor in hematology

Sorbonne Université Faculté de Médecine

FRANCE
View details

Jose Carlos Machado

Principal Investigator

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto

PORTUGAL
View details

Robert BALLOTTI

Head, team1

INSERM

FRANCE
View details

Daniel Klionsky

Alexander G. Ruthven Professor of Life Sciences

University of Michigan

UNITED STATES
View details

Sacha NAHON-ESTEVE

Université Côte d'Azur

FRANCE
View details

Gregory Grossman

Chief Scientific Officer

-

UNITED STATES
View details

Barnabé Romeo

Université Côte d'Azur

FRANCE
View details

Jonathan Benzaquen

Université Côte d'Azur

FRANCE
View details

Arnaud MARTEL

-

FRANCE
View details

Reinhard Büttner

Head of Department

University of Cologne

GERMANY
View details

Simon Heeke

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Bauke Ylstra

Director Tumor Genome Analysis Core

Amsterdam University Medical Centers

NETHERLANDS
View details

Giancarlo Troncone

-

ITALY
View details

Jeremie Roux

Inria Centre de Recherche Sophia Antipolis Méditerranée

FRANCE
View details

Nuria Malats

Group Leader

Centro Nacional de Investigaciones Oncológicas

SPAIN
View details

Carmelo Rizzari

Professor

University of Milano-Bicocca

ITALY
View details

Ed Schuuring

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Teodora Radonic

Amsterdam University Medical Centers

NETHERLANDS
View details

Patrick Brest

Senior Scientist

Université Côte d'Azur

FRANCE
View details

Valérie Vouret-Craviari

Université Côte d'Azur

FRANCE
View details

Riziero Esposito Abate

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details